Using Cinacalcet to Treat the Hypophosphatemia of Early Kidney Transplant

Status Terminated

Clinical Trial Summary

The purpose of the study is to determine whether cinacalcet, used in patients with secondary hyperparathyroidism to control excessive parathyroid hormone, can normalize low blood phosphorus that is commonly seen in patients who have had a kidney transplant.

Clinical Trial Description

Secondary hyperparathyroidism (SHPT), common in ESRD, persists following renal transplantation resulting in profound hypophosphatemia. This can lead to hemolysis, congestive heart failure, rhabdomyolysis. Phosphate repletion is difficult in view of the persistent SHPT: oral phosphate supplementation can lead to hypocalcemia, reduced 1,25-OH Vitamin D production, hypercalcemia and further hyperparathyroidism. In addition, phospho-soda has been associated with phosphate nephropathy and renal failure. Cinacalcet HCl is a calcimimetic agent that has recently become a standard therapy in the treatment of SHPT in ESRD. It suppresses PTH secretion by acting as a modulator of the Calcium-sensing receptor on the PTH cell, causing the PTH cell to decrease production of parathyroid hormone. It is a very effective agent, producing significant reduction of PTH as well as improvement in calcium and phosphate metabolism in the dialysis patient. The drug is well-tolerated with minimal adverse effects. Cinacalcet has also been used to control hypercalcemia in renal transplant patients with persistent hyperparathyroidism. Short-term cinacalcet given for 2 to 4 weeks has normalized serum phosphorus and decreased urinary phosphate wasting in renal transplant recipients with stable graft function. We hypothesize that Cinacalcet HCl will normalize the hypophosphatemia of early renal transplant by reducing the effects of PTH on the proximal renal tubular transport of phosphorus, thereby allowing phosphate reabsorption and decreasing urinary phosphate wasting. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01011114
Study type	Interventional
Source	Montefiore Medical Center
Contact
Status	Terminated
Phase	N/A
Start date	November 2009
Completion date	October 15, 2015

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01220050` - Paricalcitol in Reducing Parathyroid Hormone Levels and Ameliorating Markers of Bone Remodelling in Renal Transplant Recipients With Secondary Hyperparathyroidism	Phase 2
Completed	`NCT00820469` - Study of the Influence of Plasma Exchange on the Pharmacokinetics of Rituximab	Phase 4
Completed	`NCT00239005` - Enteric-Coated Mycophenolate Sodium on Quality of Life in Patients With Gastrointestinal Symptoms Related to Mycophenolate Mofetil Therapy After Kidney Transplantation	Phase 4
Completed	`NCT00270153` - The Use of ACE Inhibitors in the Early Renal Post-transplant Period	Phase 1
Completed	`NCT02711826` - Treg Therapy in Subclinical Inflammation in Kidney Transplantation	Phase 1/Phase 2
Completed	`NCT03837522` - Trial to Define the Benefits and Harms of Deceased Donor Kidney Procurement Biopsies	N/A
Not yet recruiting	`NCT06025240` - Expanding the Scope of Post-transplant HLA-specific Antibody Detection and Monitoring in Renal Transplant Recipients
Completed	`NCT01256294` - Pharmacokinetics of Generic to Brand Tacrolimus in Stable Renal Transplant Patients	Phase 4
Suspended	`NCT01059292` - TIPE2 Associated With Kidney Transplant	N/A
Completed	`NCT00547040` - Arterial Stiffness and Calcifications in Incident Renal Transplant Recipients
Suspended	`NCT03043339` - Characterization Of the Intestinal Microbiome Evolution After Kidney Transplant Donation or Receipt
Completed	`NCT02581644` - Assessment of Effectiveness of Belatacept Patient Alert Card in Patients Following Renal Transplantation in a Sample of EU Countries	N/A
Completed	`NCT01728012` - Long-term Cardiovascular Risk Following Successful Renal Transplantation	N/A
Completed	`NCT02117596` - Calcineurin Inhibitor Based Immunosuppression Withdrawal	N/A
Completed	`NCT00555373` - Pediatric Kidney Transplant Study of Sirolimus, Mycophenolate Mofetil, and Corticosteroids vs Calcineurin Inhibitor Based Immunosuppression	N/A
Recruiting	`NCT05156086` - Safety and Effectiveness of COVID-19 Vaccine in Kidney Transplant Recipients
Completed	`NCT01334333` - Comparison of Medication Adherence Between Once and Twice Daily Tacrolimus in Stable Renal Transplant Recipients	Phase 4
Recruiting	`NCT03107858` - The Effect of Norepinephrine Versus Dopamine in Renal Transplant Recipients on Postoperative Graft Function	Phase 2/Phase 3
Completed	`NCT00352547` - Influence of Genes on Sirolimus Metabolism in Patients With Kidney Transplantation	N/A
Withdrawn	`NCT01244659` - A Randomized Study Assess the Safety and Efficacy of Tacrolimus vs Prograf® in Renal Transplantation Treatment	Phase 3